The role of inflammation in heart failure with preserved ejection fraction.
- Author:
Qi ZHANG
1
;
Yun-Er CHEN
1
;
Xin-Xin ZHU
1
;
Xia WANG
1
;
Ai-Juan QU
1
Author Information
1. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Heart Failure;
Stroke Volume/physiology*;
Hypertrophy, Left Ventricular/metabolism*;
Ventricular Dysfunction, Left/metabolism*;
Inflammation/complications*;
Obesity;
Hypertension
- From:
Acta Physiologica Sinica
2023;75(3):390-402
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure characterized by left ventricular diastolic dysfunction with preserved ejection fraction. With the aging of the population and the increasing prevalence of metabolic diseases, such as hypertension, obesity and diabetes, the prevalence of HFpEF is increasing. Compared with heart failure with reduced ejection fraction (HFrEF), conventional anti-heart failure drugs failed to reduce the mortality in HFpEF due to the complex pathophysiological mechanism and multiple comorbidities of HFpEF. It is known that the main changes of cardiac structure of in HFpEF are cardiac hypertrophy, myocardial fibrosis and left ventricular hypertrophy, and HFpEF is commonly associated with obesity, diabetes, hypertension, renal dysfunction and other diseases, but how these comorbidities cause structural and functional damage to the heart is not completely clear. Recent studies have shown that immune inflammatory response plays a vital role in the progression of HFpEF. This review focuses on the latest research progress in the role of inflammation in the process of HFpEF and the potential application of anti-inflammatory therapy in HFpEF, hoping to provide new research ideas and theoretical basis for the clinical prevention and treatment in HFpEF.
